Research Paper Volume 13, Issue 19 pp 23193—23209

Network pharmacology for systematic understanding of Schisandrin B reduces the epithelial cells injury of colitis through regulating pyroptosis by AMPK/Nrf2/NLRP3 inflammasome

Schisandrin B reduced inflammation in vivo and vitro model of colitis. (A–D) The levels of TNF-α, IL-6, IL-1β and IL-18 in colon tissue; (E–H) the levels of TNF-α, IL-6, IL-1β and IL-18 in intestinal epithelial cells. ##P

Figure 2. Schisandrin B reduced inflammation in vivo and vitro model of colitis. (AD) The levels of TNF-α, IL-6, IL-1β and IL-18 in colon tissue; (EH) the levels of TNF-α, IL-6, IL-1β and IL-18 in intestinal epithelial cells. ##P<0.01 vs control group; **P<0.01 vs DSS- induced colitis group. Control: blank control group; Colitis: DSS- induced colitis group; Colitis+SCH: DSS- induced colitis mice with Schisandrin. ##P<0.01 vs MDSO group; **P<0.01 vs LPS+ATP induced intestinal epithelial cells group. MDSO: blank control group; LPS+ATP: intestinal epithelial cells with LPS+ATP group; LPS+ATP +SCH: intestinal epithelial cells induced by LPS+ATP with Schisandrin. SCH, Schisandrin B. Data were expressed as mean ± SEM.